A new research from Oslo University focuses on a new combination therapy for prostate cancer that uses a checkpoint inhibitor and an IRE1 blocker called MKC8866.
The therapy works by blocking the IRE1 signaling pathway, which in turn reduces immunosuppressive effects in the tumor microenvironment and makes the tumor more susceptible to checkpoint inhibitors.
This combination therapy has shown promising results in mouse models, significantly reducing tumor growth and increasing the number of cancer-killing immune cells in the tumor. Researchers believe this therapy could potentially be used to treat other types of "cold" cancers that are resistant to traditional immunotherapy.
Seminal Vesicle Invasion & Senescent tumor cells.
